Companies Longboard Pharmaceuticals
Longboard Pharmaceuticals (LBPH): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Longboard Pharmaceuticals no longer files a proxy statement; its last pay data is FY2023.
CEO pay, last three years
- $1,505,915FY2022
- $2,053,804FY2023
CEO total pay was $2,053,804 in fiscal 2023, up from $1,505,915 in fiscal 2022.
FY2023: salary $610,000 · bonus $0 · stock awards $0 · option awards $986,934
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Longboard Pharmaceuticals in fiscal 2023?
As disclosed, Kevin Lind (President and Chief Executive Officer) was the highest-paid executive at Longboard Pharmaceuticals in fiscal 2023, with total compensation of $2,053,804.
How much does Longboard Pharmaceuticals spend in total on board compensation for fiscal 2023?
As disclosed, Longboard Pharmaceuticals reported total board compensation of $360,001 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Lind | $610,000 | $0 | $0 | $986,934 | $442,860 | $0 | $14,010 | $2,053,804 |
| President and Chief Executive Officer | ||||||||
| Randall Kaye | 472,500 | 0 | 0 | 443,113 | 228,690 | 0 | 16,764 | 1,161,067 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Brandi Roberts | 436,800 | 0 | 0 | 362,547 | 211,411 | 0 | 14,442 | 1,025,200 |
| Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Kevin Lind | $2,053,804 | $1,505,915 | — | ↑ +547,889 |
| Randall Kaye | 1,161,067 | 1,385,828 | — | ↓ −224,761 |
| Brandi Roberts | 1,025,200 | 861,178 | — | ↑ +164,022 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to create a direct relationship between key business performance measurements and individual bonus amounts, while using equity-based awards to align the long-term financial interests of employees with stockholders and to attract, retain, and motivate talent.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kevin Lind | Option | — | — | — | — | — | $986,934 |
| Brandi Roberts | Option | — | — | — | — | — | 362,547 |
| Randall Kaye | Option | — | — | — | — | — | 443,113 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kevin Lind | $0 | $0 | $986,934 | 0.0% |
| Brandi Roberts | 0 | 0 | 362,547 | 0.0% |
| Randall Kaye | 0 | 0 | 443,113 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brandi Roberts | Option | 37,749 | 8.56 | — |
| Brandi Roberts | Option | 48,750 | 4.2 | — |
| Brandi Roberts | Option | 94,763 | 4.35 | — |
| Kevin Lind | Option | 105,625 | 4.2 | — |
| Randall Kaye | Option | 115,821 | 4.35 | — |
| Randall Kaye | Option | 116,157 | 6 | — |
| Kevin Lind | Option | 257,965 | 4.35 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Paul J. SekhriIndependent · Board Chair · Compensation (2) (Chair) | $86,992 | $0 | $58,815 | — | $0 | $145,807 |
| Phillip M. SchneiderIndependent · Audit (1) (Chair) | 62,988 | 0 | 58,815 | — | 0 | 121,803 |
| Corinne Le GoffIndependent · Audit (1) · Nominating and Corporate Governance (3) | 55,996 | 0 | 58,815 | — | 0 | 114,811 |
| Casey C. LynchIndependent · Nominating and Corporate Governance (3) (Chair) | 53,984 | 0 | 58,815 | — | 0 | 112,799 |
| Vincent E. AurentzIndependent · Audit (1) · Compensation (2) | 50,529 | 0 | 58,815 | — | 0 | 109,344 |
| Jane TillerIndependent · Compensation (2) · Nominating and Corporate Governance (3) | 49,512 | 0 | 58,815 | — | 0 | 108,327 |
| Kevin R. LindEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $360,001 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $360,001 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Longboard Pharmaceuticals as a peer
Companies that benchmark against LBPH
5 companies name LBPH as a compensation peer
- aTYR PHARMA INCATYRFY2025
- Biohaven Ltd.BHVNFY2025
- Dianthus Therapeutics, Inc. /DE/DNTHFY2025
- Keros Therapeutics, Inc.KROSFY2025
- Oruka Therapeutics, Inc.ORKAFY2025
Each company listed discloses LBPH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named LBPH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Longboard Pharmaceuticals | 2023 | Kevin Lind | $610,000 | $0 | $986,934 | $442,860 | $2,053,804 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-05-23 | — | — | — | — | — |
| 2023 | 2023-05-25 | — | — | — | — | — |
| 2022 | 2022-05-24 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | 2024-05-23 | —a |
| 2023 | 2023-05-25 | —b |
| 2022 | 2022-05-24 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Casey C. Lynch | Director | 2024-05-23 | A | 22,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Vincent E. Aurentz | Director | 2024-05-23 | A | 22,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul J. Sekhri | Director | 2024-05-23 | A | 22,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Corinne Le Goff | Director | 2024-05-23 | A | 22,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Phillip M. Schneider | Director | 2024-05-23 | A | 22,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-06-25 | D | 100 | 21 | 2,087 | Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-08-12 | D | 16,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-08-12 | D | 6,191 | 35 | 216,856 | Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-08-12 | D | 10,476 | 35 | 361,948 | Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-08-12 | A | 16,667 | 4 | 72,501 | Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-08-12 | D | 2,217 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-08-12 | D | 80,265 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-08-12 | A | 2,217 | 4 | 9,311 | Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-08-12 | A | 80,265 | 3 | 250,684 | Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-09-16 | D | 16,666 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-09-16 | D | 1,900 | 34 | 64,668 | RSU | Form 4 ↗ |
| Randall Kaye | CMO | 2024-09-16 | D | 1,200 | 33 | 39,750 | RSU | Form 4 ↗ |
| Randall Kaye | CMO | 2024-09-16 | D | 4,200 | 32 | 133,622 | RSU | Form 4 ↗ |
| Randall Kaye | CMO | 2024-09-16 | D | 9,366 | 31 | 289,278 | RSU | Form 4 ↗ |
| Randall Kaye | CMO | 2024-09-16 | A | 16,666 | 4 | 72,497 | RSU | Form 4 ↗ |
| Randall Kaye | CMO | 2024-10-15 | D | 16,667 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-10-15 | D | 16,667 | 59 | 983,936 | RSU | Form 4 ↗ |
| Randall Kaye | CMO | 2024-10-15 | A | 16,667 | 4 | 72,501 | RSU | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-10-25 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-10-25 | A | 9,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brandi Roberts | CFO | 2024-10-25 | A | 7,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-11-13 | D | 12,808 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-11-13 | D | 80,000 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-11-13 | A | 12,808 | 3 | 40,002 | Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-11-19 | D | 30,554 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | CMO | 2024-11-19 | A | 30,554 | 6 | 183,324 | RSU | Form 4 ↗ |
| Corinne Le Goff | Director | 2024-12-02 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Corinne Le Goff | Director | 2024-12-02 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Corinne Le Goff | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Corinne Le Goff | Director | 2024-12-02 | D | 13,397 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Casey C. Lynch | Director | 2024-12-02 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Casey C. Lynch | Director | 2024-12-02 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Casey C. Lynch | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Casey C. Lynch | Director | 2024-12-02 | D | 14,428 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandi Roberts | Executive VP and CFO | 2024-12-02 | D | 7,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandi Roberts | Executive VP and CFO | 2024-12-02 | D | 15,090 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandi Roberts | Executive VP and CFO | 2024-12-02 | D | 90,580 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandi Roberts | Executive VP and CFO | 2024-12-02 | D | 119,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vincent E. Aurentz | Director | 2024-12-02 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vincent E. Aurentz | Director | 2024-12-02 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandi Roberts | Executive VP and CFO | 2024-12-02 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brandi Roberts | Executive VP and CFO | 2024-12-02 | D | 139,380 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vincent E. Aurentz | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vincent E. Aurentz | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Paul J. Sekhri | Director | 2024-12-02 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Paul J. Sekhri | Director | 2024-12-02 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Paul J. Sekhri | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Paul J. Sekhri | Director | 2024-12-02 | D | 25,461 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | Executive Vice President & CMO | 2024-12-02 | D | 9,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | Executive Vice President & CMO | 2024-12-02 | D | 17,920 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | Executive Vice President & CMO | 2024-12-02 | D | 96,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | Executive Vice President & CMO | 2024-12-02 | D | 175,946 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Randall Kaye | Executive Vice President & CMO | 2024-12-02 | D | 30,554 | 60 | 1,833,240 | Common | Form 4 ↗ |
| Corinne Le Goff | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Casey C. Lynch | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Phillip M. Schneider | Director | 2024-12-02 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Phillip M. Schneider | Director | 2024-12-02 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Phillip M. Schneider | Director | 2024-12-02 | D | 12,367 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Phillip M. Schneider | Director | 2024-12-02 | D | 25,461 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-12-02 | D | 22,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-12-02 | D | 332,134 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-12-02 | D | 325,850 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-12-02 | D | 192,783 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-12-02 | D | 255,377 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Robert Lind | Director | 2024-12-02 | D | 363,740 | 60 | 21,824,400 | Common | Form 4 ↗ |
| Randall Kaye | Executive Vice President & CMO | 2024-12-02 | D | 107,560 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Vincent E. Aurentz | Director | 2024-12-02 | D | 7,214 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (92 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kevin Lind. DEF 14A, filed 2024-04-12. Section “Executive Compensation”. As printed: 2,053,804. View filing ↗
- Section 01, Randall Kaye. DEF 14A, filed 2024-04-12. Section “Executive Compensation”. As printed: 1,161,067. View filing ↗
- Section 01, Brandi Roberts. DEF 14A, filed 2024-04-12. Section “Executive Compensation”. As printed: 1,025,200. View filing ↗
- Section 03, Kevin Lind Option. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Brandi Roberts Option. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Randall Kaye Option. DEF 14A, filed 2024-04-12. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 08, Paul J. Sekhri. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 145,807. View filing ↗
- Section 08, Phillip M. Schneider. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 121,803. View filing ↗
- Section 08, Corinne Le Goff. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 114,811. View filing ↗
- Section 08, Casey C. Lynch. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 112,799. View filing ↗
- Section 08, Vincent E. Aurentz. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 109,344. View filing ↗
- Section 08, Jane Tiller. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 108,327. View filing ↗
- Section 08, Kevin R. Lind. DEF 14A, filed 2024-04-12. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Casey C. Lynch 2024-05-23. Form 4, filed 2024-05-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vincent E. Aurentz 2024-05-23. Form 4, filed 2024-05-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul J. Sekhri 2024-05-23. Form 4, filed 2024-05-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Le Goff 2024-05-23. Form 4, filed 2024-05-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip M. Schneider 2024-05-23. Form 4, filed 2024-05-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-06-25. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-08-12. Form 4, filed 2024-08-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-09-16. Form 4, filed 2024-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-09-16. Form 4, filed 2024-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-09-16. Form 4, filed 2024-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-09-16. Form 4, filed 2024-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-09-16. Form 4, filed 2024-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-09-16. Form 4, filed 2024-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-10-15. Form 4, filed 2024-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-10-15. Form 4, filed 2024-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-10-15. Form 4, filed 2024-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-10-25. Form 4, filed 2024-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-10-25. Form 4, filed 2024-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandi Roberts 2024-10-25. Form 4, filed 2024-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-11-13. Form 4, filed 2024-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-11-13. Form 4, filed 2024-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-11-13. Form 4, filed 2024-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-11-19. Form 4, filed 2024-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-11-19. Form 4, filed 2024-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Le Goff 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Le Goff 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Le Goff 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Le Goff 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casey C. Lynch 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casey C. Lynch 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casey C. Lynch 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casey C. Lynch 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandi Roberts 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandi Roberts 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandi Roberts 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandi Roberts 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vincent E. Aurentz 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vincent E. Aurentz 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandi Roberts 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brandi Roberts 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vincent E. Aurentz 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vincent E. Aurentz 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul J. Sekhri 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul J. Sekhri 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul J. Sekhri 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul J. Sekhri 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Corinne Le Goff 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casey C. Lynch 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip M. Schneider 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip M. Schneider 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip M. Schneider 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Phillip M. Schneider 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Robert Lind 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Randall Kaye 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vincent E. Aurentz 2024-12-02. Form 4, filed 2024-12-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-24. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-05-26. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-05-24. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 360,001 + equity 0 + all other 0 = 360,001, summed across the director compensation table rows.
- Longboard Pharmaceuticals (subject), Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Longboard Pharmaceuticals's own proxy. As printed: 2,053,804. View filing ↗